Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000674776 | SCV000800171 | likely pathogenic | Bardet-Biedl syndrome 12 | 2018-05-23 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000674776 | SCV002810014 | likely pathogenic | Bardet-Biedl syndrome 12 | 2021-12-21 | criteria provided, single submitter | clinical testing | |
Invitae | RCV002531359 | SCV003525232 | pathogenic | Bardet-Biedl syndrome | 2023-09-12 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the BBS12 protein in which other variant(s) (p.Arg675*) have been determined to be pathogenic (PMID: 20827784, 21642631). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. ClinVar contains an entry for this variant (Variation ID: 558497). This variant has not been reported in the literature in individuals affected with BBS12-related conditions. This variant is present in population databases (rs745448288, gnomAD 0.003%). This sequence change creates a premature translational stop signal (p.Arg214*) in the BBS12 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 497 amino acid(s) of the BBS12 protein. |
Baylor Genetics | RCV000674776 | SCV004211688 | likely pathogenic | Bardet-Biedl syndrome 12 | 2024-02-20 | criteria provided, single submitter | clinical testing |